more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

California Biopharma Co. Uncovers Massive Oncology Breakthrough

  ()
Nurix Therapeutics Inc. (NRIX:NASDAQ) new cancer pipeline data highlights powerful targeted protein degradation advances, with analysts projecting 92% upside potential.
Tags: Biotechnology / Pharmaceuticals

Biopharma Advances High-Impact, First-of-Its-Kind Neuroreparative Drug

  ()
NervGen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) drug produced sustained neurologic and functional gains in chronic tetraplegia, positioning it for pivotal Phase 3 development.
Tags: Biotechnology / Pharmaceuticals

Brisbane Biotech Showcases Degrader Pipeline Advantages at AACR

Research Report
  ()
Nurix Therapeutics (NASDAQ: NRIX) recently showcased AACR presentations that highlighted the mechanistic superiority of the company's protein degrader platform and preclinical data across key pipeline assets, NX-1607, NRX-4972.
Tags: Biotechnology / Pharmaceuticals

AI-Designed Cancer Drug Shows In Vivo Results, Brain Penetration

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) reported new preclinical data across two oncology programs at the AACR Annual Meeting, including ATR-mTOR inhibitor efficacy and kt-3283 formulation progress.
Tags: Healthcare ServicesBiotechnology / Pharmaceuticals

Asceniv Growth, Margin Expansion, and Pipeline Optionality Drive Price Target

Research Report
  ()
Canaccord Genuity initiates coverage of ADMA Biologics Inc. (ADMA:NASDAQ), citing Asceniv's differentiated hyperimmune IVIG profile, accelerating margins from yield enhancement, and an underappreciated pipeline.
Tags: Biotechnology / Pharmaceuticals

Company Wins Back Promising Eye Disease Drug and Eyes Two Product Launches by 2028

Research Report
  ()
MeiraGTx Holdings plc. (MGTX:NASDAQ) reported three-year durability data for AAV-hAQP1 in radiation-induced xerostomia, the reacquisition of filing-ready XLRP asset bota-vec from Johnson & Johnson, and a US$100M, according to an H.C. Wainwright research note.
Tags: Biotechnology / Pharmaceuticals

Genetic Medicines Co. Reveals Transformative 'Only-of-Its-Kind' AAV Therapy Milestone

  ()
MeiraGTx Holdings Plc (MGTX:NASDAQ) reports 3-year gene therapy results, secures US$100M funding, and advances late-stage pipeline, signaling major commercial potential.
Tags: Biotechnology / PharmaceuticalsRegenerative Medicine

Massachusetts Biotech Co. Faces Major Melanoma Drug Setback

  ()
Replimune Group Inc.'s (REPL:NASDAQ) RP1 melanoma therapy hits FDA rejection, raising uncertainty around approval timelines and future market potential.
Tags: Biotechnology / Pharmaceuticals

MA Biotech Co. Downgraded to Sell After Second FDA CRL for RP-1 Melanoma BLA

Research Report
  ()
H.C. Wainwright downgraded Replimune Group (REPL:NASDAQ) to Sell after the FDA issued a second Complete Response Letter for the RP-1 plus Opdivo BLA in anti-PD1 failed melanoma.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Advances Voice-Based Intoxication Tech Aiming to Revolutionize Medical Diagnostics

  ()
MindBio Therapeutics Corp.'s (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) AI voice model analyzes 140+ biomarkers, targeting non-invasive impairment screening.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

What Do Analysts Think About the Biopharma Set on Transforming Psychiatry

  ()
Alto Neuroscience Inc. (ANRO:NYSE) is a clinical-stage biopharmaceutical company focused on transforming psychiatry through novel drug candidates.
Tags: Biotechnology / Pharmaceuticals

Canadian Biotech Co. Appoints Elite Regulatory Expert for Chile Expansion

  ()
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) appoints Chilean policy leader Felipe Leyton for the mining rollout of its AI impairment detection tech.
Tags: Medical DevicesBiotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial

Research Report
  ()
H.C. Wainwright reiterated its rating and price target on Maze Therapeutics (MAZE:NASDAQ), following KOL calls that validated the HORIZON Phase 2 dataset as biologically coherent, confirmed the diabetic cohort signal as drug-attributable proof of concept, and outlined a clear path to pivotal trials.
Tags: Biotechnology / Pharmaceuticals

California Biotech Co. Advances Depression Drug Breakthrough

  ()
Alto Neuroscience Inc. (ANRO:NYSE) pivots after mixed trial results, targeting treatment-resistant depression with analyst support and major market growth potential.
Tags: Biotechnology / Pharmaceuticals

Philly Biotech Co. Develops High-Potential Autoimmune Therapy Breakthrough

  ()
Cabaletta Bio Inc. (CABA:NASDAQ) pushes rese-cel CAR T program forward with strong clinical momentum, production scalability, and analyst-backed upside potential.
Tags: Biotechnology / Pharmaceuticals

Biotech Company Uncovers Breakthrough Canine Arthritis Treatment

  ()
Israeli co. Can-Fite BioPharma Ltd. (CANF:NYSEAmerican) teamed up with Vetbiolix to trial Piclidenoson for dogs, with Phase 2 results due Q3 2026. Yet, one analyst still rates the stock as a Hold. Read on to see why.
Tags: Biotechnology / Pharmaceuticals

Biotech Company Achieves Key Bladder Cancer Milestone in California

  ()
ImmunityBio Inc. (IBRX:NASDAQ) confirms study power sufficiency for ANKTIVA combo, supporting measurable response outcomes and maintaining timeline for 2026 BLA filing.
Tags: Biotechnology / Pharmaceuticals

Massachusetts Biotech Co. Finds High-Potential Muscle Treatment Breakthrough

  ()
Sarepta Therapeutics Inc.'s (SRPT:NASDAQ) early results reveal dose-dependent drug exposure and significant biomarker reductions for forms of muscular dystrophy.
Tags: Biotechnology / Pharmaceuticals

Biotech Price Target Raised on Strong FSHD and DM1 siRNA Data

Research Report
  ()
Wedbush Securities raised its price target on Sarepta Therapeutics Inc. (SRPT:NASDAQ), following promising Phase 1/2 data for siRNA candidates SRP-1001 in FSHD and SRP-1003 in DM1, citing superior muscle concentration and a clean safety profile versus rival programs from Novartis and Dyne Therapeutics.
Tags: Biotechnology / Pharmaceuticals

America's First Brain-Dedicated PET Scanning Clinics: A Turnaround Play for Chart-Savvy Investors?

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson explains why he thinks Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is a Strong Speculative Buy.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline

Research Report
  ()
H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics Inc. (SRPT:NASDAQ), arguing that promising but early-stage siRNA muscle concentration data in DM1 and FSHD cannot compensate for falling ELEVIDYS sales, a fatal adverse event in SRP-1003, and intensifying competition from Avidity and Dyne ahead of a potential 2030 market entry.
Tags: Biotechnology / Pharmaceuticals

Neuroscience Co. Enters Catalyst-Rich 2026 With Multiple Phase 2 Readouts and US$120M Financing

Research Report
  ()
H.C. Wainwright reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE), citing upcoming Phase 2 data readouts for ALTO-101, ALTO-300, and ALTO-100, plus US$120 million financing to advance ALTO-207 in treatment-resistant depression through Phase 3.
Tags: Biotechnology / Pharmaceuticals

Buy Rating Reaffirmed: ALTO-207 TRD Trial on Track

Research Report
  ()
Stifel reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE) after an in-line Q4 2025 earnings report.
Tags: Biotechnology / Pharmaceuticals

Durham, NC Biopharma Co. Finds High-Growth Drug Opportunity

  ()
Pelthos Therapeutics Inc. (PTHS:NYSEAmerican) delivered massive growth from its drug launch, with bullish forecasts signaling upside, according to analysts.
Tags: Biotechnology / Pharmaceuticals

Biotech Company Accelerates AI Detection Breakthrough Globally

  ()
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) advanced AI-powered screening kiosks, targeting safer operations across industrial sectors.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Showing Results: 1 to 25 of 66 Next